A groundbreaking advancement in pancreatic cancer research has emerged from the Spanish National Cancer Research Centre (CNIO), where Dr. Mariano Barbacid and his team have demonstrated the complete elimination of aggressive pancreatic tumors in mice through a targeted triple-drug therapy. Pancreatic ductal adenocarcinoma, the predominant and most aggressive form of pancreatic cancer, carries KRAS mutations in about 90 percent of cases. via @PamphletsY🚨🇪🇸 BREAKING — Spanish Scientists Cured Pancreatic Cancer in Rats. This expertise informed the current study, which posits that single-drug interventions are insufficient against pancreatic cancer’s resilience. As investigations advance, this breakthrough reinforces the value of persistent, pathway-focused research in conquering pancreatic cancer’s formidable barriers.